Is CNS Pharmaceuticals struggling financially?

Yes, by its own account. CNS Pharmaceuticals told the SEC on 14 May 2026, in Form 10-Q, that there is substantial doubt about its ability to continue as a going concern.

Going concern disclosed May 2026

30/100

Fragile

Sector: Biotech/Pharma
Market cap: $8.5M
Source filing: 10-Q 14 May 2026
Balance sheet: 30 Jun 2026

Cash runway

14months

If the burn speeds up

Empty by Aug 2027
20months

If it eases off

Empty by Mar 2028

Both rows are the same reported burn flexed 15% either way, and neither assumes the company raises a cent.

Out of cashTwo years or more

The runway math

Cash and short-term investments

$20.0M

Cash burned over the last 12 months

$13.8M

What CNS Pharmaceuticals told the SEC

…31, 2026, the Company had an accumulated deficit of approximately $ 105 million and cash of approximately $ 3 .0 million. These conditions initially raised substantial doubt about the Company's ability to continue as a going concern within twelve months of the issuance date of these financial statements. However, subsequent to March 31, 2026, on May 5, 2026, the Company completed a private placement financing…

CNS Pharmaceuticals, Inc., Form 10-Q, filed 14 May 2026.

Read the filing on SEC.gov

What this means

Not a bankruptcy filing, and not a prediction.
It is the company’s own statement, agreed with its auditor, that the doubt is material enough to disclose.
The runway is arithmetic on two reported numbers, not a forecast. Companies carry this language for years, raise money and keep going.

What else the numbers show

1163.1% share-count increase The company issued stock. Each share now owns 92.1% less of the business than a year ago, before any change in the price.
Cash burn is narrowing It is spending 52% less cash per year than it was, so the runway above is lengthening rather than shortening.

Cash runway

The runway math

What CNS Pharmaceuticals told the SEC

What this means

What else the numbers show

Other Biotech/Pharma companies that filed the doubt